Literature DB >> 10845583

Mikulicz's disease and Sjögren's syndrome.

K Tsubota1, H Fujita, K Tsuzaka, T Takeuchi.   

Abstract

PURPOSE: To characterize lacrimal gland function and lymphocyte infiltration in patients with Mikulicz's disease (MD) and Sjögren's syndrome (SS).
METHODS: Four patients with MD and 5 with SS were recruited, on whom were performed Schirmer test I (Schirmer test without anesthesia), Schirmer test with nasal stimulation, and vital staining of the ocular surface. The lacrimal gland was then biopsied and the tissues stained with CD3, CD4, CD8, B220, APO2.7, Fas, and Fas ligand (Fas-L) antibodies.
RESULTS: Although regular Schirmer test results in the MD group were less than 10 mm, those with nasal stimulation, 38.1 +/- 3.4 mm, were significantly greater than the SS group. There were minimal ocular surface changes in MD. Morphologic staining with hematoxylin and eosin was identical in both groups, but the acinar cells were stained with APO2.7 only in the SS group. There was strong Fas and Fas-L staining in SS patients but not in those with MD.
CONCLUSIONS: Lacrimal gland acinar cells in those with MD maintained their function and were not programmed for cell death. The sicca syndrome was not observed in MD patients. Although the pathology is similar for MD and SS, the difference in acinar cell apoptosis and function can explain clinical differences.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845583

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  18 in total

Review 1.  Diagnostic criteria for IgG4-related ophthalmic disease.

Authors:  Hiroshi Goto; Masayuki Takahira; Masahiro Takahira; Atsushi Azumi
Journal:  Jpn J Ophthalmol       Date:  2014-11-14       Impact factor: 2.447

2.  A Case Report of Mikulicz Syndrome.

Authors:  Dinesh Rao; Patrick Natter; Rui Fernandes; Zhiqiang Brad Wang; Sukhwinder Johnny Singh Sandhu
Journal:  J Radiol Case Rep       Date:  2017-07-31

3.  MR imaging of IgG4-related disease in the head and neck and brain.

Authors:  K Toyoda; H Oba; K Kutomi; S Furui; A Oohara; H Mori; K Sakurai; K Tsuchiya; S Kan; Y Numaguchi
Journal:  AJNR Am J Neuroradiol       Date:  2012-06-14       Impact factor: 3.825

4.  Potentially pathogenic immune cells and networks in apparently healthy lacrimal glands.

Authors:  Austin K Mircheff; Yanru Wang; Chuanqing Ding; Dwight W Warren; Joel E Schechter
Journal:  Ocul Surf       Date:  2014-11-06       Impact factor: 5.033

Review 5.  Lessons from diseases mimicking Sjögren's syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Josep Font
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 6.  A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease.

Authors:  Motohisa Yamamoto; Hiroki Takahashi; Mikiko Ohara; Chisako Suzuki; Yasuyoshi Naishiro; Hiroyuki Yamamoto; Yasuhisa Shinomura; Kohzoh Imai
Journal:  Mod Rheumatol       Date:  2006-12-20       Impact factor: 3.023

7.  Abnormal expression and function of Fas ligand of lacrimal glands and peripheral blood in Sjögren's syndrome patients with enlarged exocrine glands.

Authors:  K Tsubota; H Fujita; K Tadano; N Onoda; K Tsuzaka; T Takeuchi
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

8.  The Wistar Bonn Kobori rat, a unique animal model for autoimmune pancreatitis with extrapancreatic exocrinopathy.

Authors:  Y Sakaguchi; M Inaba; M Tsuda; G K Quan; M Omae; Y Ando; K Uchida; K Okazaki; S Ikehara
Journal:  Clin Exp Immunol       Date:  2008-02-14       Impact factor: 4.330

9.  Proteomic analysis revealed the altered tear protein profile in a rabbit model of Sjögren's syndrome-associated dry eye.

Authors:  Lei Zhou; Ruihua Wei; Ping Zhao; Siew Kwan Koh; Roger W Beuerman; Chuanqing Ding
Journal:  Proteomics       Date:  2013-08       Impact factor: 3.984

10.  Diverse mediators modulate the chloride ion fluxes that drive lacrimal fluid production.

Authors:  Shivaram Selvam; Austin K Mircheff; Samuel C Yiu
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-26       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.